Conference item : Abstract
A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 31.6KB, Terms of use)
-
- Publisher copy:
- 10.1093/annonc/mdw383.61
Authors
- Publisher:
- Oxford University Press
- Journal:
- Annals of Oncology More from this journal
- Volume:
- 27
- Issue:
- S6
- Article number:
- 1261P
- Publication date:
- 2016-10-01
- Acceptance date:
- 2016-07-20
- DOI:
- EISSN:
-
1569-8041
- ISSN:
-
0923-7534
- Subtype:
-
Abstract
- Pubs id:
-
pubs:719427
- UUID:
-
uuid:9108ca55-a19b-4f53-a76d-065fd4d411df
- Local pid:
-
pubs:719427
- Source identifiers:
-
719427
- Deposit date:
-
2018-08-17
Terms of use
- Copyright holder:
- Pacey et al
- Copyright date:
- 2016
- Notes:
- Copyright © 2016 The Authors. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This abstract was presented at the 41st ESMO Congress (ESMO 2016).
If you are the owner of this record, you can report an update to it here: Report update to this record